MXPA05009667A - Compuestos heterociclicos inmunomoduladores. - Google Patents
Compuestos heterociclicos inmunomoduladores.Info
- Publication number
- MXPA05009667A MXPA05009667A MXPA05009667A MXPA05009667A MXPA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A MX PA05009667 A MXPA05009667 A MX PA05009667A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- alk
- alkyl
- radical
- ring
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los compuestos de la formula (I) son inhibidores de CD80 y son utiles en la terapia de inmunomodulacion:( ver formula (I)) en donde R1 y R3 representan independientemente H; F; Cl; Br; -NO2; -CN; alquilo de 1 a 6 atomos de carbono sustituido opcionalmente por F o Cl; o alcoxi de 1 a 6 atomos de carbono sustituido opcionalmente por F; R4 representa un grupo de acido carboxilico (-COOH) o un ester del mismo, o -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 o -NHC(=S)NR7R6, en donde R6 representa H, o un radical de la formula -(Alq)m-Q en donde m es 0 o 1, Alq es un radical de alquileno de 1 a 12 atomos de carbono o alquenilo de 2 a 12 atomos de carbono o alquinileno de 2 a 12 atomos de carbono de cadena recta o ramificada, divalente, sustituido opcionalmente o un radical carbociclico de 3 a 12 atomos de carbono, divalente, cualquiera de estos radicales puede contener una o mas uniones de -O-, -S- o -N(R8)-, en donde R8 representa H o alquilo de 1 a 4 atomos de carbono, alquenilo de 3 a 4 atomos de carbono, alquinilo de 3 a 4 atomos de carbono o cicloalquilo de 3 a 6 atomos de carbono y Q representa H; -NR9R10, en donde R9 y R10 representan independientemente H; alquilo de 1 a 4 atomos de carbono; alquenilo de 3 a 4 atomos de carbono; alquinilo de 3 a 4 atomos de carbono; cicloalquilo de 3 a 6 atomos de carbono; un grupo ester; un grupo carbociclico o heterociclico sustituido opcionalmente; o R9 y R10 forman un anillo cuando se toman junto con el atomo de nitrogeno al cual estan unidos, anillo que es sustituido opcionalmente; y R7 representa H o alquilo de 1 a 6 atomos de carbono; o cuando se toma junto con el atomo o atomos a los cuales estan unidos R6 y R7 forman un anillo heterociclico, monociclico, sustituido opcionalmente que tiene 5, 6 o 7 atomos del anillo; y X representa un enlace o un radical divalente de la formula -(Z)n-(Alq)- o -(Alq)-(Z)n- en donde Z representa -O-, -S- o -NH-, Alq es como se define con relacion a R6 y n es 0 o 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305876A GB0305876D0 (en) | 2003-03-14 | 2003-03-14 | Immuno inhibitory heterocyclic compounds |
| GB0319429A GB0319429D0 (en) | 2003-08-19 | 2003-08-19 | Immuno Inhibitory Heterocyclic compounds |
| PCT/GB2004/001008 WO2004081011A1 (en) | 2003-03-14 | 2004-03-10 | Immunomodulating heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05009667A true MXPA05009667A (es) | 2006-01-27 |
Family
ID=32992598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05009667A MXPA05009667A (es) | 2003-03-14 | 2004-03-10 | Compuestos heterociclicos inmunomoduladores. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7276505B2 (es) |
| EP (2) | EP2284172A1 (es) |
| JP (1) | JP4892338B2 (es) |
| KR (1) | KR101133959B1 (es) |
| AT (1) | ATE489388T1 (es) |
| BR (1) | BRPI0408365B8 (es) |
| CA (1) | CA2519063C (es) |
| DE (1) | DE602004030225D1 (es) |
| DK (1) | DK1603917T3 (es) |
| EA (2) | EA009680B1 (es) |
| EC (1) | ECSP056104A (es) |
| IL (1) | IL170389A (es) |
| MX (1) | MXPA05009667A (es) |
| NO (1) | NO332136B1 (es) |
| NZ (1) | NZ541973A (es) |
| PL (2) | PL1603917T3 (es) |
| PT (1) | PT1603917E (es) |
| SI (1) | SI1603917T1 (es) |
| WO (1) | WO2004081011A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2284172A1 (en) * | 2003-03-14 | 2011-02-16 | MediGene Ltd. | Immunomodulating heterocyclic compounds |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| GB0411770D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Immuno inhibitory heterocyclic compouds |
| CA2576256C (en) * | 2004-08-09 | 2012-01-03 | Avidex Limited | Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors |
| CA2618888A1 (en) * | 2005-08-10 | 2007-02-15 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| GB0603522D0 (en) | 2006-02-22 | 2006-04-05 | Avidex Ltd | Kinase inhibition |
| WO2007108936A2 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| WO2007136668A2 (en) | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| US20100093867A1 (en) * | 2006-07-05 | 2010-04-15 | Ryoichi Matsuda | Method Of Treating Genetic Disease Caused By Nonsense Mutation |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| JP2010533725A (ja) | 2007-07-16 | 2010-10-28 | ワイス・エルエルシー | ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物 |
| EP2020404A1 (en) * | 2007-08-01 | 2009-02-04 | Bayer Schering Pharma Aktiengesellschaft | Cyanomethyl substituted N-Acyl Tryptamines |
| MX2010003155A (es) | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de ciclopropil aril amida y uso de los mismos. |
| GB201021104D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| EP2676666A1 (en) | 2012-06-20 | 2013-12-25 | Eidgenössische Technische Hochschule Zürich (ETH) | Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| AU2015315177A1 (en) * | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| EP3558992A4 (en) * | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629412A (en) | 1946-12-24 | 1949-09-20 | Geigy Ag J R | Manufacture of metallisable monoazo dyestuffs of the pyrazolone series |
| US3576637A (en) * | 1967-04-20 | 1971-04-27 | Konishiroku Photo Ind | Lith-type of emulsion containing pyrozolone |
| JPS61161285A (ja) * | 1984-12-28 | 1986-07-21 | ルセル−ユクラフ | ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物 |
| US4591589A (en) * | 1985-01-16 | 1986-05-27 | Roussel Uclaf | 2-aryl pyrazolo[4,3-c]cinnolin-3-ones |
| DE3626221A1 (de) | 1986-08-02 | 1988-02-04 | Agfa Gevaert Ag | Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder |
| EP0269030B1 (en) | 1986-11-20 | 1994-05-04 | Mitsubishi Kasei Corporation | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor |
| DE3903993A1 (de) * | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
| AR006520A1 (es) | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
| GB9713707D0 (en) | 1997-06-27 | 1997-09-03 | Merck Sharp & Dohme | Therapeutic agents |
| SE0102404D0 (sv) * | 2001-07-04 | 2001-07-04 | Active Biotech Ab | Novel immunomodulating compounds |
| WO2003004485A1 (en) | 2001-07-05 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof |
| US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| CN100347173C (zh) | 2002-11-22 | 2007-11-07 | 活跃生物技术股份公司 | 具有免疫调制活性的吡唑并喹啉 |
| AU2003287129A1 (en) | 2002-12-16 | 2004-07-09 | Active Biotech Ab | Tetracyclic immunomodulatory compounds |
| EP2284172A1 (en) | 2003-03-14 | 2011-02-16 | MediGene Ltd. | Immunomodulating heterocyclic compounds |
| GB0325644D0 (en) * | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| GB0411770D0 (en) * | 2004-05-26 | 2004-06-30 | Avidex Ltd | Immuno inhibitory heterocyclic compouds |
| CA2576256C (en) * | 2004-08-09 | 2012-01-03 | Avidex Limited | Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors |
| US20060221590A1 (en) * | 2005-03-31 | 2006-10-05 | Edoardo Campini | System and method for Advanced Mezzanine Card connection |
| GB0603522D0 (en) | 2006-02-22 | 2006-04-05 | Avidex Ltd | Kinase inhibition |
-
2004
- 2004-03-10 EP EP10014524A patent/EP2284172A1/en not_active Withdrawn
- 2004-03-10 PT PT04719006T patent/PT1603917E/pt unknown
- 2004-03-10 DK DK04719006.1T patent/DK1603917T3/da active
- 2004-03-10 NZ NZ541973A patent/NZ541973A/en not_active IP Right Cessation
- 2004-03-10 EA EA200501370A patent/EA009680B1/ru not_active IP Right Cessation
- 2004-03-10 EP EP04719006A patent/EP1603917B1/en not_active Expired - Lifetime
- 2004-03-10 PL PL04719006T patent/PL1603917T3/pl unknown
- 2004-03-10 CA CA2519063A patent/CA2519063C/en not_active Expired - Lifetime
- 2004-03-10 BR BRPI0408365A patent/BRPI0408365B8/pt not_active IP Right Cessation
- 2004-03-10 JP JP2006505937A patent/JP4892338B2/ja not_active Expired - Lifetime
- 2004-03-10 WO PCT/GB2004/001008 patent/WO2004081011A1/en active Application Filing
- 2004-03-10 SI SI200431606T patent/SI1603917T1/sl unknown
- 2004-03-10 AT AT04719006T patent/ATE489388T1/de active
- 2004-03-10 MX MXPA05009667A patent/MXPA05009667A/es active IP Right Grant
- 2004-03-10 EA EA200702435A patent/EA014080B1/ru not_active IP Right Cessation
- 2004-03-10 DE DE602004030225T patent/DE602004030225D1/de not_active Expired - Lifetime
- 2004-03-10 PL PL383655A patent/PL383655A1/pl unknown
- 2004-03-10 US US10/547,448 patent/US7276505B2/en not_active Expired - Lifetime
- 2004-03-10 KR KR1020057017070A patent/KR101133959B1/ko not_active Expired - Lifetime
-
2005
- 2005-08-18 IL IL170389A patent/IL170389A/en active IP Right Grant
- 2005-10-13 NO NO20054710A patent/NO332136B1/no unknown
- 2005-10-14 EC EC2005006104A patent/ECSP056104A/es unknown
-
2007
- 2007-08-28 US US11/845,837 patent/US7598247B2/en not_active Expired - Lifetime
-
2009
- 2009-08-24 US US12/545,902 patent/US8309552B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05009667A (es) | Compuestos heterociclicos inmunomoduladores. | |
| NZ505638A (en) | Bicyclic pyrrole derivatives as MCP-1 inhibitors | |
| MXPA04002602A (es) | Compuestos de ester y sus usos medicos. | |
| NO931433D0 (no) | 4,1-benzoksazepinderivater og deres anvendelse | |
| NO20061416L (no) | Pyrimidotiofenforbindelser | |
| IN2012DN04853A (es) | ||
| AR018892A1 (es) | Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis | |
| NZ511311A (en) | Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives useful as agricultural, horticultural bactericides | |
| PE20030969A1 (es) | Compuestos heterociclicos, activos inhibidores de beta-lactamasas | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
| NZ335157A (en) | N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis | |
| WO2005095395A3 (en) | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors | |
| EA200900616A1 (ru) | Ингибиторы ikk-бета серин-треонин протеинкиназы | |
| AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
| DE60014394D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| UA49005C2 (uk) | Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі | |
| ES2180201T3 (es) | Derivados de azetidinona para el tratamiento de infecciones por hcmv. | |
| MXPA06001039A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| YU76702A (sh) | Postupak za sintezu n-/(s)-1-karboksibutil/-(s)-alaninskih estara i njihovu upotrebu u sintezi perindoprila | |
| DE69804611D1 (de) | 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose | |
| TW200612931A (en) | Substituted biphenyl derivatives | |
| DK1163258T3 (da) | Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis | |
| GB0119863D0 (en) | DNA-PK inhibitors | |
| NZ517742A (en) | Isoindoloindolone compounds useful for treating disorders of the melatonin system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration | ||
| GB | Transfer or rights |